RWJ 56110

Key Product Details

Product Description

RWJ 56110 is a selective protease-activated receptor-1 (PAR₁) antagonist; displays no activity at PAR₂, PAR₃, or PAR₄ subtypes. Blocks thrombin-induced platelet aggregation and activation of MAPK in HUVECs. Also inhibits angiogenesis in a chick embryo angiogenesis model in vivo.

Product Specifications for RWJ 56110

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for RWJ 56110

The following data is based on the product molecular weight 863.65.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.16 mL	5.79 mL	11.58 mL
5 mM	0.23 mL	1.16 mL	2.32 mL
10 mM	0.12 mL	0.58 mL	1.16 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 30 publications citing the usage of this product.

• Zania Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J.Pharmacol.Exp.Ther. 2006 PMID: 16595737
• Andrade-Gordon Design, synthesis and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc.Natl.Acad.Sci.USA 1999 PMID: 10535908
• Maryanoff Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr.Med.Chem.Cardiovasc.Hematol.Agents 2003 PMID: 15317288

Product Documents for RWJ 56110